Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) reports interim data from a study, which suggests that multiple sclerosis patients who switched to Copaxone from interferon-beta treatment showed a significant reduction in spasticity.
Interim results for the first 52 of 110 participants revealed a significant reduction in muscle stiffness, pain and discomfort, as well as the effect of spasticity on the ability to walk, body movements and activities of daily living. Improvement was also found in reduction of total spasticity scores during the six month period.
Teva' presented the results at the 64th Annual Meeting of the American Academy of Neurology in New Orleans.
"Spasticity, one of the more common symptoms of multiple sclerosis, can often negatively impact patients' daily lives," said principal investigator Dr. Cira Fraser, Associate Professor at the Marjorie Unterberg School of Nursing and Health Studies, Monmouth University in New Jersey. "These data may suggest a reduction in the key measures of spasticity in multiple sclerosis patients who discontinued interferon-beta treatment and transitioned to Copaxone."
Teva SVP Global Brand Strategic Marketing Jon Congleton added, "These study results contribute to the body of knowledge on the treatment of multiple sclerosis."
Published by Globes [online], Israel business news - www.globes-online.com - on April 29, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012